miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma by Khella, H W Z, Bakhet, M, Allo, G, Jewett, M A S, Girgis, A H, Latif, A, Girgis, H, Von Both, I, Bjarnason, G A, Yousef, G M

Get full text

Does the Time of Radiotherapy Affect Treatment Outcomes? A Review of the Literature by Chan, S, Rowbottom, L, McDonald, R, Bjarnason, G.A, Tsao, M, Danjoux, C, Barnes, E, Popovic, M, Lam, H, DeAngelis, C, Chow, E

Get full text

Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium by Stukalin, I, Wells, J C, Graham, J, Yuasa, T, Beuselinck, B, Kollmansberger, C, Ernst, D S, Agarwal, N, Le, T, Donskov, F, Hansen, A R, Bjarnason, G A, Srinivas, S, Wood, L A, Alva, A S, Kanesvaran, R, Fu, S Y F, Davis, I D, Choueiri, T K, Heng, D Y C

Get full text

Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma by Hotte, S J, Bjarnason, G A, Heng, D Y C, Jewett, M A S, Kapoor, A, Kollmannsberger, C, Maroun, J, Mayhew, L A, North, S, Reaume, M N, Ruether, J D, Soulieres, D, Venner, P M, Winquist, E W, Wood, L, Yong, J H E, Saad, F

Get full text

PCN22 CLINICAL HETEROGENEITY AMONG FIRST-LINE SUNITINIB PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) CATEGORIZED AS INTERMEDIATE RISK (IR) GROUP ACCORDING TO THE INTERNATIO... by Huynh, L., Wells, J.C., Graham, J., Steinharter, J., McGregor, B., Donskov, F., Bjarnason, G.A., Vaishampayan, U., Hansen, A., Iafolla, M., Zanotti, G., Chang, R., Cheng, W.Y., Duh, M.S., Heng, D.Y.C.

Get full text

1107 Outcomes of patients with non clear cell renal cell carcinoma treated with targeted therapy and prognostication using the International mRCC Database Consortium Criteria by Kroeger, N, Xie, W, Lee, J-L, Bjarnason, G.A, Knox, J.J, Mackenzie, M.J, Wood, L, Srinivas, S, Vaishamayan, U.N, Rha, S.Y, Pal, S.K, Yuasa, T, Donskov, F, Agarwal, N, Kollmannsberger, C.K, Tan, M.H, North, S.A, Rini, B.I, Choueiri, T.K, Heng, D.Y.C

Get full text

Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma by Hotte, S J, Bjarnason, G A, Heng, D Y C, Jewett, M A S, Kapoor, A, Kollmannsberger, C, Maroun, J, Mayhew, L A, North, S, Reaume, M N, Ruether, J D, Soulieres, D, Venner, P M, Winquist, E W, Wood, L, Yong, J H E, Saad, F

Get full text

247 SUNITINIB IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS (PTS) WITH BRAIN METASTASES (METS): DATA FROM AN EXPANDED-ACCESS STUDY by Bracarda, S, Hariharan, S, Szczylik, C, Porta, C, Hawkins, R, Bjarnason, G.A, Oudard, S, Lee, S.H, Carteni, G, Gore, M

Get full text

248 SUNITINIB IN PATIENTS (PTS) WITH OR WITHOUT PRIOR NEPHRECTOMY IN AN EXPANDED-ACCESS STUDY OF METASTATIC RENAL CELL CARCINOMA (MRCC) by Szczylik, C, Porta, C, Bracarda, S, Hawkins, R, Bjarnason, G.A, Oudard, S, Kee, S.H, Carteni, G, Hariharan, S, Gore, M

Get full text